WS

W. Schenk

1 records found

166Ho is a promising radionuclide for targeted radionuclide therapy, because of its beneficial decay characteristics and the possibility to track its dose delivery in a patient. However, a problem for the use of 166Ho in these treatments is its limited maximally produced specific ...